Pipeline Regulatory Progress -- Two risk-adjusted product launches (AMP-002 and AMP-015) are included in the flat full-year ...

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to ...

Venofer was approved in the U.S. in 2000. It was developed by Vifor Pharma, which is now part of CSL Ltd. American Regent, a unit of Daiichi Sankyo, manufactures and sells it in the U.S. under a ...

Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 10.4% in the morning session after the company announced it received U.S. Food and Drug Administration (FDA) approval for ...

Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Greetings, and welcome to the Amphastar Pharmaceuticals’ Second ...

Investing.com -- Amphastar Pharmaceuticals (NASDAQ: AMPH) stock gained 4% after the company announced FDA approval for its generic version of iron sucrose injection, a treatment for iron deficiency ...

NasdaqGS:AMPH 1 Year Share Price vs Fair Value Explore Amphastar Pharmaceuticals's Fair Values from the Community ...

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer® for the treatment of iron deficiency anemia in patients with chro ...

Amphastar Pharmaceuticals (NASDAQ:AMPH) saw its stock increase by 4% after the company announced that the FDA had approved ...

Amphastar is undervalued (~71% upside), but lacks an economic moat and faces modest growth, so I favor a cautious gradual ...

On a per-share basis, the Rancho Cucamonga, California-based company said it had profit of 64 cents. Earnings, adjusted for one-time gains and costs, were 85 cents per share. The results exceeded Wall ...

The outlook for AMP-002 and AMP-015 includes the potential for approval and contribution to 2025 revenue, with risk-adjusted expectations. Management expects increased price competition on glucagon, ...